Pfizer is launching a new competitive grants program to support research projects investigating the role of PCSK9 in health and cardiovascular disease.

In clinical trials, PCSK9 inhibitors have been shown to reduce the level of LDL cholesterol levels by up to 60%, achieving a much greater affect than currently available therapies, even in difficult-to-treat patients.

Pfizer itself is currently studying the investigational PCKS9 inhibitor bococizumab in Phase III trials for its potential to lower LDL cholesterol and improve cardiovascular outcomes.

The drug giant’s new annual funding programme will dish out multiple grants of up to $100,000 each to support research designed to uncover new insights about the role of the PCSK9 protein/gene in health and disease.

Investigators are now being invited to submit applications for innovative research in several areas, including the pathophysiology of dyslipidaemia and atherosclerotic vascular disease, PCSK9 in the immune system, and PCSK9 in infectious disease. 

The competition is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program.